» Articles » PMID: 20160274

Accuracy of Perceived Risk of Recurrence Among Patients with Early-stage Breast Cancer

Overview
Date 2010 Feb 18
PMID 20160274
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Accurate breast cancer recurrence risk perceptions might motivate health-promoting behaviors and alleviate undue anxiety. Although a few studies have examined early-stage breast cancer survivors' perceived risk of recurrence, none have assessed the accuracy of survivors' perceived risk of recurrence.

Methods: First primary ductal carcinoma in situ and early-invasive breast cancer survivors reported their perceived risk of recurrence during 6- and 12-month postsurgery interviews. We estimated the patients' 10-year risk of recurrence from published clinical trials, and for early-invasive breast cancer patients, risk of distant recurrence was based on their breast cancer-specific mortality calculated using Adjuvant! Online. Patients' perceived risk was compared with their calculated risk and categorized as "Accurate," "Underestimated," "Overestimated," and "Uncertain." Multinomial logit marginal effect models were fitted using Accurate as the reference.

Results: Only 17% of 531 patients accurately perceived their risk at 6 months, most of whom inaccurately perceived their risk at 12 months (P = 0.0143). Patients who were nonwhite [odds ratio (OR), 1.70; 95% confidence interval (95% CI), 1.12-2.56] and received radiation therapy (OR, 2.01; 95% CI, 1.07-3.77) were more likely to underestimate their risk. Patients with ductal carcinoma in situ (OR, 1.76; 95% CI, 1.11-2.79), [corrected] lower social support (OR, 0.71; 95% CI, 0.53-0.95), and anxiety (OR, 1.58; 95% CI, 1.01-2.47) were more likely to overestimate their risk.

Conclusion: Few breast cancer survivors accurately perceived their risk of recurrence.

Impact: The accuracy of perceived risk may be increased by better physician-patient communications about their prognosis, provision of social support, and treatment for coexisting anxiety.

Citing Articles

Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors.

Ankersmid J, Lansink Rotgerink F, Strobbe L, van Uden-Kraan C, Siesling S, Drossaert C Breast Cancer Res Treat. 2022; 195(2):117-125.

PMID: 35907105 PMC: 9362565. DOI: 10.1007/s10549-022-06684-3.


Accuracy of Perceived Breast Cancer Risk in Black and White Women with an Elevated Risk.

Young J, Postula K, Duquette D, Gutierrez-Kapheim M, Pan V, Katapodi M Ethn Dis. 2022; 32(2):81-90.

PMID: 35497400 PMC: 9037653. DOI: 10.18865/ed.32.2.81.


Patient opinions on contralateral prophylactic mastectomy: A patient-driven discussion in need of tuning?.

Brown Z, Schellenberg A, Cordeiro E, Holloway C, Scheer A, Eisen A Can J Surg. 2022; 65(2):E250-E256.

PMID: 35365498 PMC: 8979655. DOI: 10.1503/cjs.003420.


Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches.

Cescon D, Kalinsky K, Parsons H, Smith K, Spears P, Thomas A Front Oncol. 2022; 11:667397.

PMID: 35223447 PMC: 8867255. DOI: 10.3389/fonc.2021.667397.


Gaps in Care and Support for Patients With Advanced Breast Cancer: A Report From the Advanced Breast Cancer Global Alliance.

Fallowfield L, Boyle F, Travado L, Kiely B, Jewell P, Aubel D JCO Glob Oncol. 2021; 7:976-984.

PMID: 34156869 PMC: 8457864. DOI: 10.1200/GO.21.00045.


References
1.
Goodwin A, Parker S, Ghersi D, Wilcken N . Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. 2009; (1):CD000563. DOI: 10.1002/14651858.CD000563.pub4. View

2.
Fisher B, Dignam J, Wolmark N, Wickerham D, Fisher E, Mamounas E . Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999; 353(9169):1993-2000. DOI: 10.1016/S0140-6736(99)05036-9. View

3.
. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

4.
Sammarco A . Quality of life among older survivors of breast cancer. Cancer Nurs. 2004; 26(6):431-8. DOI: 10.1097/00002820-200312000-00002. View

5.
Bartelink H, Horiot J, Poortmans P, Struikmans H, Van Den Bogaert W, Barillot I . Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2002; 345(19):1378-87. DOI: 10.1056/NEJMoa010874. View